Sanofi continues to deliver strong business

Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1  Paris, April 28, 2022 Q1 2022 sales growth of 8.6% at CER driven by Dupixent® and CHC Specialty Care grew 17.8% driven by Dupixent® (€1,614 million, +45.7%) Vaccines were up 6.8% reflecting strong […]

Subscribe US Now